# Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms

> **NCT05124691** · PHASE2,PHASE3 · TERMINATED · sponsor: **Barcelona Institute for Global Health** · enrollment: 1001 (actual)

## Conditions studied

- Helminthes; Infestation, Intestinal

## Interventions

- **COMBINATION_PRODUCT:** Albendazole and Ivermectin fixed dose coformulation
- **DRUG:** Albendazole

## Key facts

- **NCT ID:** NCT05124691
- **Lead sponsor:** Barcelona Institute for Global Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-20
- **Primary completion:** 2023-03-21
- **Final completion:** 2023-03-24
- **Target enrollment:** 1001 (ACTUAL)
- **Why stopped:** Primary Endpoint met
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05124691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05124691, "Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05124691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*